Proteostasis Therapeutics, Inc. Announces Pricing of Initial Public Offering
February 11 2016 - 7:21AM
Proteostasis Therapeutics, Inc. today announced the pricing of its
initial public offering of 6,250,000 shares of common stock at a
public offering price of $8.00 per share, before underwriting
discounts and commissions. All of the common stock is being offered
by Proteostasis Therapeutics, Inc. In addition, the company has
granted the underwriters a 30-day option to purchase up to an
additional 937,500 shares of common stock from the company at the
public offering price. The company’s shares are expected to begin
trading on the NASDAQ Global Market on February 11, 2016 under the
ticker symbol “PTI.” The offering is expected to close on February
17, 2016 subject to customary closing conditions.
Leerink Partners and RBC Capital Markets are acting as joint
book-running managers. Baird and H.C. Wainwright & Co. are
acting as co-managers.
A registration statement relating to the securities being sold
in the offering was declared effective by the Securities and
Exchange Commission on February 10, 2016. This offering is being
made only by means of a prospectus. Copies of the final prospectus
relating to this offering may be obtained by contacting: Leerink
Partners LLC, c/o Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA 02110, or by email at
syndicate@leerink.com, or by phone at (800) 808-7525, ext. 6142; or
RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey
Street, 8th Floor, New York, NY 10281, Telephone: (877)
822-4089, Email: equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
Media Contact:
Dan Budwick, Pure Communications
dan@purecommunicationsinc.com
973-271-6085
Investor Contact:
Luke Heagle, Pure Communications
luke@purecommunicationsinc.com
910-726-1372
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Apr 2023 to Apr 2024